Deborah B. Doroshow

Hematology | Oncology

1470 Madison Ave Fl 3
New York, NY 10029

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 51 publications

Erratum: Resistance to Immune Checkpoint Inhibitor Treatment in Non-Small Cell Lung Cancer Clinical Trials: A Perspective From Lung-MAP Investigators.

Erratum: Resistance to Immune Checkpoint Inhibitor Treatment in Non-Small Cell Lung Cancer Clinical Trials: A Perspective From Lung-MAP Investigators.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: July 08, 2026

Resistance to Immune Checkpoint Inhibitor Treatment in Non-Small Cell Lung Cancer Clinical Trials: A Perspective From Lung-MAP Investigators.

Resistance to Immune Checkpoint Inhibitor Treatment in Non-Small Cell Lung Cancer Clinical Trials: A Perspective From Lung-MAP Investigators.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: June 03, 2026

Resistance to Immune Checkpoint Inhibitor Treatment in Non-Small Cell Lung Cancer Clinical Trials: A Perspective From Lung-MAP Investigators.

Resistance to Immune Checkpoint Inhibitor Treatment in Non-Small Cell Lung Cancer Clinical Trials: A Perspective From Lung-MAP Investigators.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: June 03, 2026

Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing biliary tract or pancreatic tumors: a subgroup analysis of DESTINY-PanTumor02.

Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing biliary tract or pancreatic tumors: a subgroup analysis of DESTINY-PanTumor02.

Journal: ESMO open

Published: March 17, 2026

Evolving Trends in Latin American Participation in Global Oncology Clinical Trials: A Decade of Phase III Activity (2013-2022).

Evolving Trends in Latin American Participation in Global Oncology Clinical Trials: A Decade of Phase III Activity (2013-2022).

Journal: JCO global oncology

Published: February 20, 2026

Who Wins? Professional Identity and the American Association for the History of Medicine's Early Career Scholar Awards.

Who Wins? Professional Identity and the American Association for the History of Medicine's Early Career Scholar Awards.

Journal: Journal of the history of medicine and allied sciences

Published: November 18, 2025

Targeted therapy for DNA damage response and homologous recombination repair defects: The Olaparib Combinations trial.

Targeted therapy for DNA damage response and homologous recombination repair defects: The Olaparib Combinations trial.

Journal: Cancer

Published: August 03, 2025

Real-World Outcomes and Subsequent Treatment Patterns in Patients with Advanced Non-Small Cell Lung Cancer and Atypical EGFR Mutations Receiving First-Line Osimertinib Monotherapy.

Real-World Outcomes and Subsequent Treatment Patterns in Patients with Advanced Non-Small Cell Lung Cancer and Atypical EGFR Mutations Receiving First-Line Osimertinib Monotherapy.

Journal: Oncology and therapy

Published: August 01, 2025

Documentation of patient withdrawals, retention strategies, and postwithdrawal data practices in cancer clinical trials.

Documentation of patient withdrawals, retention strategies, and postwithdrawal data practices in cancer clinical trials.

Journal: Cancer

Published: May 19, 2025

Inpatient Immunotherapy Outcomes Study: A Multicenter Retrospective Analysis.

Inpatient Immunotherapy Outcomes Study: A Multicenter Retrospective Analysis.

Journal: JCO oncology practice

Published: February 12, 2025

Azenosertib Is a Potent and Selective WEE1 Kinase Inhibitor with Broad Antitumor Activity Across a Range of Solid Tumors.

Azenosertib Is a Potent and Selective WEE1 Kinase Inhibitor with Broad Antitumor Activity Across a Range of Solid Tumors.

Journal: Molecular cancer therapeutics

Published: December 23, 2024

Financial Toxicity Among Patients With Advanced Solid Tumors Participating in Early-Phase Clinical Trials.

Financial Toxicity Among Patients With Advanced Solid Tumors Participating in Early-Phase Clinical Trials.

Journal: JCO oncology practice

Published: December 11, 2024

Showing 1-12 of 51

Last Updated: 09/26/2026